Liver Cancer Therapeutics Market Size

Liver Cancer Therapeutics Market size was over USD 2.99 billion in 2023 and is anticipated to reach USD 26.87 billion by 2036, witnessing around 18.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of liver cancer therapeutics is estimated at USD 3.43 billion. The growth of the market is attributed to growing prevalence of liver cancer over high alcohol consumption, non-alcoholic fatty liver disease, and rise in incidence of hepatitis B infection in developing countries. According to the World Health Organisation, liver cancer was ranked third in the most common causes of cancer death in the world in 2020, causing nearly 830,000 deaths, while in 2019, hepatitis B resulted in an estimated 820,000 deaths globally.

Moreover, increasing R&D activities and advancement in cancer therapeutics with emergence of targeted therapies, and increasing public awareness leading to higher demand for treatment are further expected to foster the growth of the market.

However, high cost and side effects related to certain liver cancer therapies, such as gastrointestinal diseases, hair loss, fatigue, skin diseases, etc. are one of the key factors restraining the growth of the market. Moreover, limitations in treatment options with several therapies in clinical trial stage are further expected to hinder the market growth.